MedTech firm Ocutrx announced its AR headset, OcuLenz, at the CES ShowStoppers event. The headset will retail at USD 6,000 within the first half of 2024 and is currently discounted to USD 4,500 for pre-orders. The target audience for the headset includes low-vision centers, optometrists, ophthalmologists, and individuals.

The OcuLenz headset is specifically designed to address vision loss issues in adults over 65 caused by advanced macular degeneration. Key features include a 2.5K per eye resolution with a 72° field of view (FOV), and the headset is powered by Qualcomm’s Snapdragon XR2 processor. 

The company also has a patented interpupillary distance adjustment to prevent dizziness. Further, Ocutrx’s software development kit (SDK) extends the OcuLenz use to fields such as the military and enterprise sectors. 

Analyst QuickTake: The company’s acquisition of electronics manufacturing and assembly company Spectrum Advanced Manufacturing Technologies in April 2023 provided it with the necessary infrastructure to produce its OcuLenz headset in compliance with FDA standards within the US.